The Neurovascular Properties of Dental Stem Cells and Their Importance in Dental Tissue Engineering

Jessica Ratajczak, Annelies Bronckaers, Yörg Dillen, Pascal Gervois, Tim Vanganssewinkel, Ronald B. Driesen, Esther Wolfs, Ivo Lambrichts, and Petra Hilkens

Laboratory of Morphology, Biomedical Research Institute (BIOMED), Hasselt University, Diepenbeek, Belgium

Correspondence should be addressed to Petra Hilkens; petra.hilkens@uhasselt.be

Received 26 May 2016; Accepted 1 August 2016

Copyright © 2016 Jessica Ratajczak et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Within the field of tissue engineering, natural tissues are reconstructed by combining growth factors, stem cells, and different biomaterials to serve as a scaffold for novel tissue growth. As adequate vascularization and innervation are essential components for the viability of regenerated tissues, there is a high need for easily accessible stem cells that are capable of supporting these functions. Within the human tooth and its surrounding tissues, different stem cell populations can be distinguished, such as dental pulp stem cells, stem cells from human deciduous teeth, stem cells from the apical papilla, dental follicle stem cells, and periodontal ligament stem cells. Given their straightforward and relatively easy isolation from extracted third molars, dental stem cells (DSCs) have become an attractive source of mesenchymal-like stem cells. Over the past decade, there have been numerous studies supporting the angiogenic, neuroprotective, and neurotrophic effects of the DSC secretome. Together with their ability to differentiate into endothelial cells and neural cell types, this makes DSCs suitable candidates for dental tissue engineering and nerve injury repair.

1. Introduction

The main goal of tissue engineering is to reconstruct natural tissues by combining progenitor/stem cells with growth factors and different biomaterials to serve as a scaffold for novel tissue growth [1]. Selecting a suitable stem cell source is probably the most essential component of a successful tissue engineering approach. The field of tissue engineering is in need of high-quality adult stem cells from an easily accessible source. Within the human body a wide variety of stem cell niches have been identified, not only in bone marrow, adipose tissue, and umbilical cord but also in teeth [2–6]. During tooth development, an outer layer of enamel and an inner layer of primary dentin are formed by reciprocal, spatiotemporal interactions between neural crest-derived mesenchyme and embryonic oral epithelium [7, 8]. Primary dentin is produced by odontoblasts, cells that are thought to arise from precursor cells residing in a strongly innervated and vascularized soft connective tissue within the tooth, that is, the dental pulp. In 2000, Gronthos et al. were the first to describe a heterogeneous, clonogenic, and highly proliferative cell population within the dental pulp, namely, dental pulp stem cells (DPSCs) [4]. A similar stem cell population could also be isolated from the dental pulp of human deciduous teeth [9]. In addition to DPSCs and stem cells from human exfoliated deciduous teeth (SHEDs), a number of other distinct stem cell populations have been reported to reside within the human tooth and its surrounding tissues. For example, stem cells from the apical papilla (SCAPs) can be found in the loosely attached soft connective tissue at the apex of developing permanent teeth, that is, the apical papilla [10]. Dental follicle stem cells (FSCs), on the other hand, are isolated from the dental follicle. This is a loose connective tissue which surrounds developing teeth and later on in development gives rise to the periodontal ligament and other tissues of the periodontium [11]. The periodontal ligament, a specialized connective tissue, not only attaches the tooth to the alveolar bone but also has a sensory function. Within this ligament, another stem cell population can be found, namely, periodontal ligament stem cells (PDLSCs) [12]. According to
the minimal criteria defined by the International Society for Cellular Therapy, DPSCs, SHEDs, SCAPs, FSCs, and PDLSCs (collectively referred to as dental stem cells (DSCs)) are considered to be mesenchymal stem cells (MSCs). In addition to their plastic adherence and characteristic expression of surface markers such as CD73, CD90, and CD105, they also display a negative expression of CD14, CD34, and CD45, and they are capable of osteogenic, chondrogenic, and adipogenic differentiation [4, 13–15]. Next to the formation of dental tissue *in vitro* and *in vivo*, DSCs have also been reported to differentiate into myogenic, neurogenic, and endothelial lineages. Due to this multilineage differentiation potential as well as their immunomodulatory properties and minimally invasive isolation from extracted third molars, these stem cells have raised high hopes for potential clinical applications [16–21]. Nevertheless, one should always take into account potential origin-related differences. In general, SCAPs and FSCs are considered to be more immature, given their origin from developing dental tissues, and thus more potent in comparison to DPSCs. SCAPs have already been reported to have a higher proliferation rate, a more distinct doubling capacity, and enhanced migratory properties in comparison to DPSCs [10]. Furthermore, the glial origin of a subpopulation of DPSCs suggests that the tissue of origin is a determining factor for the regenerative potential of DSCs [22, 23]. In order to offer an elaborate overview of the angiogenic and neurogenic properties of different DSC populations as well as their current clinical applications in the dental and neurovascular field, a literature search was performed on PubMed. The following keywords were used: “dental stem cells”; “dental pulp stem cells”; “stem cells from the apical papilla”; “stem cells from human exfoliated deciduous teeth”; “dental follicle stem cells”; “periodontal ligament stem cells”. These keywords were subsequently combined with the search terms, “angiogenesis”; “endothelial differentiation”; “neurogenic differentiation”; “neuroregeneration”; “dental tissue engineering”; “dental pulp regeneration”; “periodontal regeneration”; “peripheral nerve injury”, without any set limitations regarding the type or year of publication.

2. Dental Stem Cells and Angiogenesis

Within the healthy human body, the most predominant and most studied form of blood vessel formation is angiogenesis. In general, angiogenesis can be defined as the sprouting of new capillaries from preexisting blood vessels in response to specific stimuli such as inflammation or hypoxia [42, 43]. This well-coordinated biological process is regulated by a broad range of proteins, which maintain a natural balance between stimulatory and inhibitory signaling pathways. As the latter are considered to be dominant, endothelial cells normally remain quiescent within the healthy human body [44]. However, in pathological conditions such as ischemic stroke, myocardial infarction, cancer, and diabetes, this balance is disturbed [45].

Since deprivation of oxygen and nutrients, due to a lack in vascular supply, can lead to tissue necrosis, angiogenesis also plays an important role in tissue engineering. However, the limited success of growth factor-based revascularization urged the need to promote angiogenesis with a more regenerative approach by means of stem cell-based therapies [46, 47]. MSCs are considered to establish therapeutic angiogenesis by either paracrine secretion of angiogenic growth factors or differentiation into endothelial cells [48–50].

2.1. Paracrine Mediation of Angiogenesis by Dental Stem Cells.

With regard to the angiogenic properties of DSCs, studies have indicated the secretion of a broad range of regulatory proteins. DPSCs, for example, have been reported to express stimulatory growth factors such as platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF), and vascular endothelial growth factor (VEGF), either in basal conditions or in response to noxious stimuli, for example, injury or hypoxia [17, 28, 29, 34, 35]. Other angiogenesis-promoting factors that have been detected in DPSCs are angiogenin (ANG), angiopoietin-1 (ANGPT1), colony-stimulating factor (CSF), dipeptidyl peptidase IV (DPPIV), endothelin-1 (EDN1), interleukin-8 (IL-8), insulin-like growth factor binding protein-3 (IGFBP3), monocyte chemoattractant protein-1 (MCP-1), and urokinase-type plasminogen activator (uPA) [24, 30]. Nevertheless, the secretome of DPSCs also comprises several inhibitory proteins, such as endostatin, pentraxin-3 (PTX-3), pigment epithelium-derived factor (PEGF), plasminogen activator inhibitor-1 (PAI-1), tissue inhibitor of matrix metalloproteinase-1/4 (TIMP-1/4), and thrombospandin-1 (THBS-1) [24, 30]. Comparable findings were also described for SCAPs and FSCs, albeit with variable expression levels between the different stem cell populations [16, 24–26, 31, 51]. With regard to the secretome of SHEDs and PDLSCs, literature indicates the expression of ANGPT2 [27], bFGF [16, 27, 32], endostatin [16], hepatocyte growth factor (HGF) [33], insulin-like growth factor-1 (IGF-1) [27], and VEGF [27, 32, 33, 36]. An overview of the DSC secretome and its associated functions can be found in Table 1 [44, 45, 52]. One should take into account the fact that not all growth factor functions have already been described for DSCs.

Since DSCs express a wide variety of angiogenesis regulating proteins, stimulatory as well as inhibitory, it is important to determine their potential impact on the behavior of endothelial cells and angiogenesis altogether. Each well-coordinated event within the angiogenic process can be mimicked by a series of *in vitro* assays. For instance, colorimetric assays are performed to evaluate the effect of DSC-derived growth factors on endothelial proliferation. A significant increase of both survival and proliferation of human umbilical vein endothelial cells (HUVECs) was observed after incubation with conditioned medium (CM) of a CD31+/CD146− subpopulation of DPSCs [53]. Aranha et al. also reported a time-dependent increase in the proliferation of human dermal microvascular endothelial cells (HMECs) when incubated with CM of hypoxia-preconditioned DPSCs [34]. Hilkens et al., on the other hand, reported no pronounced effect of CM of DPSCs, SCAPs, and FSCs on the proliferation of human microvascular endothelial cells (HMECs) [24]. To date, the potential effect of SHEDs and PDLSCs on endothelial proliferation has not been described. In order to evaluate whether endothelial cells migrate along a gradient...
Table 1: The secretome of dental stem cells and its associated functions.

<table>
<thead>
<tr>
<th>Factor</th>
<th>Function</th>
<th>Population</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Angiogenesis-stimulating factors</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Angiogenin (ANG)</td>
<td>Endothelial proliferation and migration. Activation of smooth muscle cells. Indirect degradation of basement membrane.</td>
<td>DPSCs, SCAPs, and FSCs</td>
<td>[24]</td>
</tr>
<tr>
<td>Angiopoietin-1 (ANGPT1)</td>
<td>Endothelial survival, migration, and matrix adhesion. Endothelial sprouting and vessel stabilization.</td>
<td>DPSCs, SCAPs, and FSCs</td>
<td>[24–26]</td>
</tr>
<tr>
<td>Angiopoietin-2 (ANGPT2)</td>
<td>Endothelial proliferation, migration, and sprouting in the presence of VEGF.</td>
<td>PDLSCs</td>
<td>[27]</td>
</tr>
<tr>
<td>Basic fibroblast growth factor (bFGF)</td>
<td>Endothelial proliferation, migration, and tube formation. Upregulation of uPA, VEGF receptor, and integrins.</td>
<td>DPSCs, SCAPs, SHEDs, and PDLSCs</td>
<td>[16, 26–32]</td>
</tr>
<tr>
<td>Colony stimulating factor (CSF)</td>
<td>Endothelial proliferation, migration, and differentiation. Induction of proteolytic enzyme release.</td>
<td>DPSCs</td>
<td>[17]</td>
</tr>
<tr>
<td>CXC chemokines, for example, interleukin-8 (IL-8)</td>
<td>Endothelial survival, proliferation, migration, and tube formation. Induction of MMP production.</td>
<td>DPSCs</td>
<td>[30]</td>
</tr>
<tr>
<td>Dipeptidyl peptidase IV (DPPIV)</td>
<td>Vascular remodeling. Endothelial proliferation, migration, and tube formation.</td>
<td>DPSCs, SCAPs, and FSCs</td>
<td>[24]</td>
</tr>
<tr>
<td>Endothelin-1 (EDN1)</td>
<td>Endothelial proliferation and migration. Stimulation of VEGF-mediated angiogenesis. Stimulation of endothelial MMP2 production. Proliferation of vascular smooth muscle cells.</td>
<td>DPSCs, SCAPs, and FSCs</td>
<td>[24]</td>
</tr>
<tr>
<td>Hepatocyte growth factor (HGF)</td>
<td>Endothelial proliferation, migration, and tube formation. Proliferation of vascular smooth muscle cells. Stimulation of VEGF and PIGF production.</td>
<td>SCAPs, SHEDs</td>
<td>[25, 26, 33]</td>
</tr>
<tr>
<td>Insulin-like growth factor-1 (IGF-1)</td>
<td>Endothelial proliferation, migration, and tube formation. Stimulation of VEGF and plasminogen activator production. Downregulation of endothelial apoptosis.</td>
<td>PDLSCs</td>
<td>[27]</td>
</tr>
<tr>
<td>Insulin-like growth factor binding protein-3 (IGFBP3)</td>
<td>Endothelial migration and tube formation. Stimulation of IGF-1-mediated angiogenesis. Stimulation of VEGF and MMP2 production.</td>
<td>DPSCs, SCAPs, and FSCs</td>
<td>[24, 26, 30]</td>
</tr>
<tr>
<td>Matrix metalloproteinases (MMPs)</td>
<td>Extracellular matrix degradation and release of sequestered growth factors.</td>
<td>DPSCs, SCAPs</td>
<td>[17, 25]</td>
</tr>
<tr>
<td>Monocyte chemotactic protein (MCP-1)</td>
<td>Endothelial chemotaxis, tube formation, and differentiation. Stimulation of HIF-1α and VEGF production.</td>
<td>DPSCs, SCAPs</td>
<td>[26, 30]</td>
</tr>
<tr>
<td>Platelet-derived growth factor (PDGF)</td>
<td>Endothelial proliferation, migration, and differentiation. Stimulation of VEGF expression. Proliferation of vascular smooth muscle cells and pericytes. Vessel stabilization.</td>
<td>DPSCs</td>
<td>[28]</td>
</tr>
<tr>
<td>Urokinase-type plasminogen activator (uPA)</td>
<td>Participation in ECM degradation and release of sequestered growth factors. Endothelial migration and invasion. Activation of VEGF and pro-VEGF.</td>
<td>DPSCs, SCAPs, and FSCs</td>
<td>[24, 26, 30]</td>
</tr>
<tr>
<td>Vascular endothelial growth factor (VEGF)</td>
<td>Endothelial proliferation, migration, and tube formation. Stimulation of NO synthase and plasminogen activator expression. Downregulation of endothelial apoptosis.</td>
<td>DPSCs, SCAPs, FSCs, SHEDs, and PDLSCs</td>
<td>[17, 24–36]</td>
</tr>
<tr>
<td><strong>Angiogenesis-inhibiting factors</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ANGPT2</td>
<td>Natural antagonist of ANGPT1. Upregulation of endothelial apoptosis.</td>
<td>PDLSCs</td>
<td>[27]</td>
</tr>
<tr>
<td>DPP IV</td>
<td>Inhibition of endothelial progenitor homing. Inhibition of CXCR3-induced chemotaxis.</td>
<td>DPSCs, SCAPs, and FSCs</td>
<td>[24]</td>
</tr>
<tr>
<td>Endostatin</td>
<td>Endothelial proliferation and migration. Upregulation of endothelial apoptosis. Inhibition of MMPS and bFGF-mediated and VEGF-mediated angiogenesis.</td>
<td>DPSCs, SCAPs, and SHEDs</td>
<td>[16, 30]</td>
</tr>
<tr>
<td>Factor</td>
<td>Function</td>
<td>Population</td>
<td>Reference</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------</td>
<td>---------------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>IGFBP3</td>
<td>Endothelial migration and tube formation. Inhibition of MMP9 and VEGF production.</td>
<td>DPSCs, SCAPs, and FSCs</td>
<td>[24, 26, 30]</td>
</tr>
<tr>
<td>MMPs</td>
<td>Inhibition of FGFR1 and uPAR-mediated signaling. Generation of angiogenic inhibitors by proteolytic cleavage.</td>
<td>DPSCs</td>
<td>[17]</td>
</tr>
<tr>
<td>Pentraxin-3 (PTX-3)</td>
<td>Inhibition of bFGF-mediated angiogenesis.</td>
<td>DPSCs, SCAPs, and FSCs</td>
<td>[24, 26]</td>
</tr>
<tr>
<td>Pigment epithelium-derived factor (PEGF)</td>
<td>Endothelial proliferation and migration. Uregulation of endothelial apoptosis.</td>
<td>DPSCs, SCAPs, and FSCs</td>
<td>[24, 26]</td>
</tr>
<tr>
<td>Plasminogen activator inhibitor (PAI-1)</td>
<td>Inhibition of uPA.</td>
<td>DPSCs, SCAPs, and FSCs</td>
<td>[24, 26, 30]</td>
</tr>
<tr>
<td>Thrombospondin-1 (THBS1)</td>
<td>Endothelial proliferation, migration, and tube formation. Uregulation of endothelial apoptosis.</td>
<td>DPSCs, SCAPs, and FSCs</td>
<td>[24, 26]</td>
</tr>
<tr>
<td>Tissue inhibitor of MMPs-1/4 (TIMP-1/4)</td>
<td>Inhibition of MMPs</td>
<td>DPSCs, SCAPs, and FSCs</td>
<td>[24, 26, 30]</td>
</tr>
<tr>
<td><strong>Neurotrophic factors</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basic fibroblast growth factor (bFGF)</td>
<td>Neuronal differentiation. Neurite outgrowth.</td>
<td>DPSCs, SCAPs, SHEDs, and PDLSCs</td>
<td>[16, 26–32]</td>
</tr>
<tr>
<td>Brain-derived neurotrophic factor (BDNF)</td>
<td>Survival of neurons. Differentiation of neuroblasts. Formation of synapses and neuritogenesis.</td>
<td>DPSCs, SCAP</td>
<td>[37–41]</td>
</tr>
<tr>
<td>Ciliary neurotrophic factor (CNTF)</td>
<td>Neuronal survival.</td>
<td>DPSCs</td>
<td>[40]</td>
</tr>
<tr>
<td>Glial-cell derived neurotrophic factor (GDNF)</td>
<td>Survival of neurons. Differentiation of neuroblasts. Neuroitogenesis.</td>
<td>DPSCs, SCAPs</td>
<td>[37, 38]</td>
</tr>
<tr>
<td>Nerve growth factor (NGF)</td>
<td>Survival, maintenance, and proliferation of neurons. Neurite outgrowth.</td>
<td>DPSCs, SCAPs</td>
<td>[37, 38, 40, 41]</td>
</tr>
<tr>
<td>Neurotrophin-3 (NT-3)</td>
<td>Survival of neurons. Differentiation of neuroblasts. Neuroitogenesis.</td>
<td>DPSCs</td>
<td>[38, 40]</td>
</tr>
<tr>
<td>Neurotrophin-4 (NT-4)</td>
<td>Survival of neurons. Differentiation of neuroblasts. Neuroitogenesis.</td>
<td>DPSCs</td>
<td>[40]</td>
</tr>
<tr>
<td>PDGF-AA</td>
<td>Neuronal survival. Neuritogenesis.</td>
<td>DPSCs</td>
<td>[40]</td>
</tr>
<tr>
<td>VGF (VGF nerve growth factor inducible)</td>
<td>Neuronal survival. Neuritogenesis.</td>
<td>DPSCs</td>
<td>[40]</td>
</tr>
</tbody>
</table>

of DSC-derived chemokines, a transwell migration assay is performed. DPSCs as well as SCAPs have been shown to significantly augment endothelial migration in comparison to FSCs [24, 30]. In terms of endothelial tubulogenesis, Yuan et al. indicated an increased formation of capillary-like structures during a direct coculture of SCAPs and HUVECs [54]. Similar outcomes were found for DPSCs, SHEDs, and PDLSCs [29, 32, 55–57]. During these direct cocultures, DSCs are thought to adopt a pericyte-like function as they are often found in close proximity to the endothelial cells [54, 56, 57]. Alternatively, endothelial tube formation can also be mediated by paracrine factors, as was shown by Dissanayaka et al. through an indirect coculture of DPSCs and HUVECs [58]. In line with these findings, Tran-Hung et al. and others reported a significant increase in endothelial tubulogenesis caused by CM of DPSCs [24, 29]. With regard to the impact of PDLSCs and SHEDs on the functional behavior of endothelial cells, more extensive research is required.

The angiogenic properties of DSCs have also been elaborately investigated in vivo. Yeasmin et al., for example, indicated significant vascularization after subcutaneous transplantation of PDLSCs and endothelial cells. Since there was no detection of human-derived blood vessels, PDLSCs were considered to secrete paracrine mediators or to act as pericytes [32]. Mouse DPSCs were found to induce angiogenesis in a VEGF-dependent manner in a mouse Matrigel.
plug assay [56]. DPSCs and SCAPs also caused a significant increase in angiogenesis in a chorioallantoic membrane assay [24, 30]. In terms of more clinically relevant disease models, Gandia et al. demonstrated a significant improvement of left ventricular function after injection of GFP-labeled DPSCs in a rat model of myocardial infarction. Apart from a reduction in infarct size and thickening of the anterior ventricular wall, an increase in capillary density was also detected. As there were no signs of differentiated DPSCs within the heart tissue, the aforementioned improvement was probably mediated by paracrine factors [59]. These findings were supported by Iohara et al., who reported a high capillary density after transplantation of a CD31+/CD146− subpopulation of DPSCs in a mouse model of hindlimb ischemia. The close location of the stem cells near the newly formed blood vessels suggests a paracrine role for DPSCs [53]. The abovementioned subpopulation of DPSCs also promoted functional recovery in rats suffering from focal cerebral ischemia. Besides neurotrophic factors, the authors also demonstrated augmented levels of VEGF, which potentially played a role in the stimulation of vasculosurgery and neurogenesis in the ischemic rat brain [60, 61].

2.2. Endothelial Differentiation Potential of Dental Stem Cells.

As stated before, MSCs not only contribute to therapeutic angiogenesis by secreting angiogenic growth factors but also are able to differentiate into endothelial cells under specific environmental cues. With regard to the endothelial differentiation potential of DPSCs, d’Aquino et al. were the first to report on the so-called codifferentiation of these cells into osteoblasts and endotheliocytes. Following the in vitro osteogenic differentiation of a sorted CD117+/CD34+/VEGFR2− DPSC population, flow cytometric analysis demonstrated a subpopulation of VEGFR2+/Stro-1+/CD44+/CD34− endothelial progenitor cells with a marked expression of von Willebrand factor (vWF) and angiotensin-converting enzyme (ACE) [62]. Similar results were found by Marchionni et al., indicating the expression of vWF and CD54 as well as the increased presence of VEGFR1 and VEGFR2, after incubating DPSCs with VEGF for 7 days. In addition, these cells were able to form capillary-like structures when seeded on Matrigel or cultured in a fibrin clot [63]. Extensive capillary network formation was also observed by Barachini et al., as well as the in vitro expression of CD31 and VEGFR2. Functionality of the differentiated cells was successfully established with the uptake of acetylated low density lipoprotein [64]. These findings confirm earlier observations made by Iohara et al., reporting the in vitro endothelial differentiation potential of a CD31+ / CD146− subpopulation of DPSCs [53]. However, the efficacy of endothelial differentiation is dependent on not only the addition of specific growth factors to the cell culture medium, but also the concentration of fetal bovine serum (FBS) and the cell seeding density appear to play an important role. Karbanová et al., for example, demonstrated the upregulation of CD31, CD34, CD106, and VWF after culturing DPSCs at a low density in serum-free differentiation medium. When cells were seeded at a higher density, no upregulation of VWF was observed. The addition of FBS maintained cell proliferation and the endothelial phenotype of DPSCs [65]. In addition to DPSCs, SHEDs have also been shown to differentiate into endothelial cells. In 2008, Cordeiro et al. detected beta-galactosidase-positive capillaries in transplanted tooth slices containing LacZ-transduced SHEDs [66]. The same researchers later on confirmed these results in vitro and in vivo, indicating capillary sprouting and the VEGF-induced expression of VEGFR2, CD31, and VE-cadherin and a continuous expression of VEGFRI by SHEDs [67, 68]. In particular VEGFRI appears to play an important role in the endothelial differentiation potential of SHEDs and DPSCs. This was demonstrated by a reduction of human CD31-positive capillaries, following transplantation of VEGFRI-silenced SHEDs in a tooth slice model in vivo. The importance of the VEGFRI/MEK1/ERK signaling cascade was illustrated in vitro by the complete suppression of endothelial differentiation following the inhibition of this signaling pathway [67]. Recent work of Zhang et al. also revealed the Wnt/β-catenin pathway to be an important regulator of the endothelial fate of DPSCs and SHEDs [69]. With regard to the endothelial differentiation potential of other DSC populations, limited data are available. Bakopoulou et al. recently demonstrated the acquisition of a preendothelial phenotype by SCAPs, after exposure to an angiogenic induction medium for 28 days in normoxic conditions. These cells not only were able to form capillary-like structures but also displayed a time-dependent upregulation of different marker proteins, such as CD31, VWF, VEGFR2, angiopoietin-1/2, and Tie-1. Moreover, when depriving SCAPs of oxygen and nutrients, their endothelial differentiation potential appeared to be more pronounced [26]. After induction of differentiation for different periods of time, both a significant upregulation of endothelial marker proteins and the formation of tubules were observed in a CD105+/enriched subpopulation of PDLSCs. Molecular analysis illustrated the critical role of neuropilin-2 (NRP-2) in the angiogenic fate of these stem cells [70]. To date, evidence for the in vivo endothelial transdifferentiation of DSCs remains scarce. As previously mentioned, Zhang and colleagues observed the presence of human CD31+ blood vessels after transplanting human DPSCs and SHEDs in a rodent tooth slice model [67, 69]. However, DSCs are mainly considered to assume a pericyte-like phenotype, as they are often located adjacent to endothelial cells in vitro as well as in vivo [32, 54–57, 71, 72].

3. Dental Stem Cells and Neuroregeneration

3.1. Paracrine Mediation of Neuroprotection and Neurite Outgrowth by Dental Stem Cells.

DSCs also produce a wide variety of neurotrophic factors and therefore they can be used in tissue engineering as a growth factor delivery system. These neurotrophic factors play a pivotal role in protecting neurons from apoptosis and inducing endogenous neural repair and neurite formation. Brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), glial cell-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and various others are abundantly present in the secre- tome of DPSCs and SCAPs (Table 1) [25, 38, 40, 41, 73–77]. The neurotrophic factors secreted by SHEDs, PDLSCs,
or FSCs remain to be characterized. Mead et al. demonstrated that DPSCs expressed more NGF, BDNF, and VEGF than bone marrow-derived mesenchymal stem cells (BM-MSCs) and adipose tissue-derived mesenchymal stem cells (AMSCs) [40]. Another research group revealed that SCAPs secreted significantly larger amounts of chemokines and neurotrophins in comparison to BM-MSCs, whereas BM-MSCs secreted more extracellular matrix (ECM) proteins and proangiogenic factors [25]. Interestingly, the capacity of DPSCs to increase neurite outgrowth of neurons of dorsal ganglia was even more pronounced after these cells were differentiated into Schwann cells [38]. In addition, another study showed that after differentiation into neurons, DPSCs expressed more VEGF and NGF but less BDNF [78].

In comparison to other DSC populations, there is abundant evidence on the beneficial effect of DPSCs on neuroprotection and neurotigenesis in vitro. DPSCs were found to rescue sensory and dopaminergic neurons from apoptosis [79] and induce the survival and sprouting of neurons of trigeminal [75], retinal [40, 80], and sympathetic ganglia [38, 81]. SHED CM also enhances the viability and neuritogenesis of neurons of dorsal root ganglia [82]. A recent paper showed that exosomes derived from SHEDs grown on laminin-coated three-dimensional algaline microcarriers are able to suppress 6-hydroxy-dopamine-induced apoptosis in dopaminergic neurons [83]. DPSCs significantly enhanced neuritogenesis of axotomized rat retinal ganglia compared to BM-MSCs and AMSCs and possessed superior neuroprotective properties. The addition of specific Fc-receptor inhibitors revealed that VGF nerve growth factor inducible (VGF) was the responsible factor released by DPSCs [40]. Finally, DPSCs were shown to be superior to BM-MSCs in rescuing astrocytes from cell death induced by oxygen-glucose deprivation [84]. DPSCs are also able to guide the differentiation process of neural precursor cells: rat neural stem cells cultured on P(EA-co-HEA)90/10 biomaterials covered with DPSCs differentiated into young TuJ1-immunoreactive neurons [73].

Numerous studies have demonstrated the beneficial effects of DPSCs in injuries and pathologies of nervous system. In the pioneer study of Arthur et al., DPSCs were able to attract trigeminal neurons after transplantation into chicken embryos [76, 81]. As mentioned above, neurogenic predifferentiated DPSCs were also able to integrate in the host brain of a rat [85]. Intravitreal injection of DPSCs promotes neuronal survival and axon regeneration of retinal ganglia cells after optic nerve injury in rats [39]. In a rat model of spinal cord injury, transplantation of both SHEDs and DPSCs improved recovery of hindlimb locomotor functions. In the same experiment, BM-MSCs or skin-derived fibroblasts caused substantially less recovery of locomotor function. The proposed mechanisms were inhibition of apoptosis of neurons, astrocytes, and oligodendrocytes and regeneration of transected axons [86]. In rodent models of ischemic stroke, transplantation of DPSCs and SHEDs also led to an improvement in neurobehavioral function [61, 87–90]. This could be due to a decrease of inflammation, an increase of angiogenesis, or a reduction of apoptosis. Nagpal et al. announced the first clinical trial to apply autologous DPSCs as a therapy for patients with chronic disability after stroke, the so-called TOOTH trial (The Open study Of dental pulp stem cell Therapy in Humans, TOOTH) [91]. Both SHEDs and DPSCs differentiated to dopaminergic neurons have been shown to improve functional behavior in a rat model of Parkinson’s disease. The therapeutic success was attributed to the induction of neurite outgrowth and neuronal survival caused by various neurotrophic factors [92]. Very recently it was described that a single injection of SHED CM in mice suffering from experimental autoimmune encephalomyelitis not only significantly improved disease scores and reduced demyelination and axonal injury but also reduced inflammatory cell infiltration and proinflammatory cytokine levels in vivo [93].

Studies describing the neuroprotective effects of FSCs, SCAPs, or PDLSCs are scarce. In a coculture system with rat trigeminal ganglia, SCAPs were able to stimulate and guide neurite outgrowth in vitro. This effect was completely inhibited by neutralizing antibodies directed against BDNF but no effect was observed when NGF and GDNF were blocked. In addition, axonal growth was shown to be triggered after subcutaneous injection of a Matrigel containing SCAPs into immunodeficient mice [37]. Furthermore, SCAPs were also applied in a rat model of spinal cord injury. However, the functional outcome was better in animals which received implantation of a whole apical papilla compared to animals which received in vitro expanded SCAPs [94]. FSCs seeded on aligned electrospun poly(e-caprolactone)/poly-DL-lactide-co-glycolide fibers were also applied as a cellular therapy in a spinal cord injury model, but no significant functional improvement was observed after transplantation [95].

3.2. Neuronal and Neural Differentiation Potential of Dental Stem Cells. As DSCs are embryonically derived from the neural crest and glial tissues, it is not surprising that these cells display neurogenic properties. Multiple protocols are available in literature to induce differentiation of DSCs into neurons in vitro. These procedures involve either the incubation of DSC monolayers with a cocktail of various growth factors and pharmacological compounds or the generation of floating neurospheres of DSCs, which recapitulates the embryonic stages of neuroblast formation (for a detailed review, see [74, 96]). In general, the mostly applied proteins to induce neuronal differentiation of DSC monolayers include epidermal growth factor (EGF) and bFGF in combination with culture supplements such as B27, forskolin, and insulin-transferrin-sodium selenite (ITS). All DSC populations have been shown to differentiate into neuron-like cells. Although successful differentiation was verified by means of an increased expression of neuronal markers such as NeuN, neural cell adhesion molecule, neurofilament, synaptophysin, A2B5, and microtubule-associated protein-2, ultrastructural and/or electrophysiological analysis of the differentiated cells was lacking in most of these studies. Furthermore, these differentiation protocols mostly result in a low yield of neurons, which are primitive, immature, and not able to produce a train of action potentials [78]. However, studies of Kiraly et al. demonstrated that predifferentiated DPSCs integrated into the host brain when transplanted into the cerebrospinal fluid
of 3-day-old rats with a cortical injury. These cells displayed neuronal properties, not only by expressing neurofilament and NeuN but also by exhibiting voltage-dependent sodium and potassium channels [85]. DSCs that were injected into the brain of rodents after stroke predominantly differentiated into astrocytes instead of neurons [87]. As DSCs represent a very heterogeneous stem cell population, sorting the cells prior to neuronal induction might increase the success rate of differentiation.

Recent evidence indicates that DSCs also differentiate into oligodendrocytes and Schwann cells, which myelinate neurons from the central and peripheral nervous system, respectively. Transfection of the helix-loop-helix transcription factor Olig2 in DPSCs resulted in an increased expression of oligodendrocyte markers such as nestin, NG2, and myelin basic protein [97]. In addition, Martens et al. reported the differentiation of DPSCs into Schwann cells. The differentiated cells displayed an increased expression of laminin, low-affinity nerve growth factor receptor p75, glial fibrillary acidic protein, and CD104. Moreover, these cells were able to myelinate neurons in vitro, which was confirmed by ultrastructural analysis [38]. The ability of DPSCs to differentiate into Schwann cells might be explained by the fact that a significant population of the DPSCs are embryonically derived from peripheral nerve-associated glia [22] and might thus represent a dedifferentiation. Whether other DSCs are capable of differentiating into myelinating cells remains to be investigated. Because of their capacity to differentiate into Schwann cells, DPSCs might represent a promising strategy to treat peripheral nerve injury. Nerve autografts are the current gold standard treatment in the clinic. As this involves sacrifice of other nerves and the clinical results are usually unsatisfactory, other options are currently under investigation [98]. Despite their key role in endogenous nerve repair, transplantation of Schwann cells themselves is very restricted as their isolation also requires destruction of another nerve and their expansion rates are dramatically low [98–100]. In a rat model of facial nerve injury, DPSCs were shown to promote remyelination, blood vessel formation, and nerve regeneration when applied in combination with silicon, collagen I, or poly(lactic-co-glycolic acid) (PLGA) tubes [101–103]. SHEDs were also applied to treat rat sciatic nerve injury. Bridging the nerve gap with silicon conduits containing CM of SHEDs resulted in a higher number of myelinated axons than controls [82]. Finally, one study reported the use of PDLSCs in peripheral nerve injury. Injection of PDLSCs into the crush-injured left mental nerve of rats significantly improved sensory function and increased the number or retrograde labeled sensory neurons and myelinated axons [104].

Despite the fact that under controlled circumstances DSCs are able to differentiate into cells resembling to neurons, Schwann cells, and oligodendrocytes, the current paradigm is that their beneficial effects in preclinical models of neurodegenerative diseases and traumas are caused by the cytokines and growth factors in their secretome.

### 4. Preconditioning of Dental Stem Cells to Enhance Their Angiogenic and Neurogenic Properties

One of the major hurdles in the field of tissue engineering is the survival of transplanted cells in vivo. To overcome this obstacle, several strategies have been developed to modulate the stem cells prior to transplantation in order to improve cellular survival and engraftment [105]. Genetic modification offers a potential strategy to increase stem cell survival, for example, by overexpressing antiapoptotic genes such as Bcl-2 [106] or Akt [107, 108]. Another possibility is to modify the expression of a key protein of a certain illness such as dopamine for Parkinson's patients or insulin for diabetics [109]. However, genetic modification is a new and developing field and many questions remain to be resolved before clinical applications using genetically modified stem cells can be deemed possible [109].

Preparing stem cells for transplantation by exposing them to a hypoxic environment may be a useful technique to improve the stem cell secretome, since hypoxia is a potent stimulus for the secretion of a variety of trophic factors (Table 2) [105, 124]. Hypoxic preconditioning has already been shown to ameliorate cell survival, paracrine activity, and angiogenic potency in a model of murine hindlimb ischemia [125–127]. Oxygen levels in the dental pulp are lower compared to other tissues, since oxygen can only be supplied via blood vessels running through the rather narrow apical foramen of the tooth [128]. Culturing DPSCs under hypoxic conditions increases their proliferation rate [110, 111], VEGF expression [34], and migration [112]. Moreover, hypoxia also upregulates VEGF production in SCAPs [26, 31] and cells from the periodontal ligament [118]. These reports all support the beneficial effects of hypoxic preconditioning. However, mimicking hypoxia by simply adding a pharmacological agent would greatly increase the feasibility of this approach (Table 2). Prolyl hydroxylase (PHD) inhibitors represent such a group of hypoxia mimicking agents. PHD inhibitors include not only iron chelators such as hinokitiol, deferoxamine, or L-mimosine but also cobalt chloride and dimethylxalylglycine [119, 129]. These PHD inhibitors promote VEGF secretion and HIF-1α expression in dental pulp-derived cells [113, 114], SCAPs [123], and PDL cells [119] and even in a tooth slice organ culture model [130]. Furthermore, preconditioned DPSCs [115] and SCAPs [123] also enhance capillary network formation by HUVECs. In addition, the application of hinokitiol-stimulated DPSCs in a mouse Matrigel plug assay resulted in an increased hemoglobin content and PECAM-1 expression [114]. Taken together, these reports suggest a promising future for the use of hypoxic mimicry in preparing stem cells for in vivo transplantation. HIF-1α and its downstream targets stimulate not only angiogenesis but also neurogenesis. For this reason, hypoxic preconditioning offers new prospects with regard to neuroregeneration. Despite the promising results using BM-MSCs [131–133] and embryonic stem cells [134], no reports were found using preconditioned DSCs for the treatment of neurological disorders.
Table 2: Dental stem cells and the effects of preconditioning.

<table>
<thead>
<tr>
<th>Priming</th>
<th>(Angiogenic) effect</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dental pulp stem cells</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypoxia</td>
<td>Increased proliferation rate</td>
<td>[110, 111]</td>
</tr>
<tr>
<td>PHD inhibitors</td>
<td>Increased HIF-1α and VEGF expression/secretion</td>
<td>[34]</td>
</tr>
<tr>
<td>PHD inhibitors</td>
<td>Increased migration</td>
<td>[112]</td>
</tr>
<tr>
<td>Hifokitiol</td>
<td>Increased HIF-1α and VEGF expression/secretion</td>
<td>[113]</td>
</tr>
<tr>
<td>FGF-2</td>
<td>Increased hemoglobin content in mouse matrigel plug assay</td>
<td>[114]</td>
</tr>
<tr>
<td>Lipopolysaccharide (LPS)</td>
<td>Enhanced EC capillary network formation</td>
<td>[115]</td>
</tr>
<tr>
<td>Hypoxia</td>
<td>Increased VEGF expression</td>
<td>[116, 117]</td>
</tr>
<tr>
<td>PHD inhibitors</td>
<td>Increased HIF-1α and VEGF expression/secretion</td>
<td>[118]</td>
</tr>
<tr>
<td>IL-1α</td>
<td>Increased VEGF expression</td>
<td>[36]</td>
</tr>
<tr>
<td>TNF-α</td>
<td>Increased VEGF expression</td>
<td>[120]</td>
</tr>
<tr>
<td>Adiponectin</td>
<td>Increased proliferation rate</td>
<td>[121]</td>
</tr>
<tr>
<td>Lipopolysaccharide (LPS)</td>
<td>Increased migration</td>
<td>[112]</td>
</tr>
<tr>
<td>Hypoxia</td>
<td>Increased VEGF expression</td>
<td></td>
</tr>
<tr>
<td>PHD inhibitors</td>
<td>Increased HIF-1α and VEGF expression/secretion</td>
<td></td>
</tr>
<tr>
<td>IL-1α</td>
<td>Increased VEGF expression</td>
<td></td>
</tr>
<tr>
<td>TNF-α</td>
<td>Increased VEGF expression</td>
<td></td>
</tr>
<tr>
<td>Adiponectin</td>
<td>Increased proliferation rate</td>
<td></td>
</tr>
<tr>
<td>Lipopolysaccharide (LPS)</td>
<td>Increased migration</td>
<td>[122]</td>
</tr>
<tr>
<td>Hypoxia</td>
<td>Increased VEGF expression</td>
<td></td>
</tr>
<tr>
<td>PHD inhibitors (CoCl₂)</td>
<td>Increased HIF-1α and VEGF expression/secretion</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Enhanced EC capillary network formation</td>
<td></td>
</tr>
</tbody>
</table>

To conclude, there are several more cytokines, growth factors, or chemical agents that can be used to boost the angiogenic potential of DSCs (Table 2). For example, bacterial lipopolysaccharide (LPS) has been shown to enhance VEGF secretion of DPSC [116, 117] and the migration of FSCs [122]. Pretreatment of PDLSCs with IL-1α [36] and TNF-α [120] leads to a more pronounced VEGF secretion, whereas adiponectin exposure increases PDLC proliferation rate and wound healing capabilities [121].

5. Dental Stem Cells and Pulp Regeneration

Although dental pulp can be characterized as a specialized tissue with a number of important physiological functions, it is also very vulnerable to caries, infections, and trauma. As any of these insults can easily interfere with normal pulp homeostasis and subsequently affect normal root development, the endodontic treatment of necrotic, immature permanent teeth in particular poses many challenges [135–137]. Over the past decade, substantial advances have been made regarding the potential application of DSCs in the regeneration of viable dental tissues. Not only has successful dental pulp regeneration been reported for DPSCs, but also SCAPs and FSCs have proven to be effective in different in vivo models of pulp regeneration.

Even before the definition and characterization of DPSCs, Mooney et al. already demonstrated the establishment of pulp-like tissue in vitro when culturing human pulp fibroblasts onto polyglycolic acid (PGA) matrices for 60 days [138]. In line with these findings, Buurma et al. reported fibroblast survival and ECM production within the PGA constructs after subcutaneous transplantation in immunocompromised mice [139]. Around the same time, Gronthos et al. and others described the presence of a stem cell population within the dental pulp, namely, DPSCs, which was able to form a vascularized dentin/pulp-like complex in vivo when cotransplanted with hydroxyapatite/tricalcium phosphate particles (HA/TCP) in immunocompromised mice [4, 14, 140]. These findings led to the development of other proof-of-principle models such as the tooth slice/scaffold model, which comprises the application of an emptied human tooth slice containing a supportive scaffold [141]. A number of studies have pointed out the regeneration of vascularized pulp-like tissue after subcutaneous implantation of tooth slices containing either DPSCs or SHEDs supported by a biodegradable scaffold [66, 67, 69, 141, 142]. Another proof-of-principle model, which illustrates the limited vascular supply within the tooth, is the ectopic root transplantation model. In 2010, Huang et al. described the de novo formation of a vascularized dentin/pulp complex in a subcutaneously
transplanted emptied human root canal enclosing a PLGA scaffold seeded with DPSCs [143]. Similar observations were made by Rosa et al., showing the formation of vascularized dentin/pulp-like tissue after subcutaneous implantation of SHEDs and a self-assembling peptide hydrogel in emptied human root canals [144]. A specific, granulocyte colony-stimulating factor- (G-CSF-) mobilized subpopulation of DPSCs was also found to regenerate vascularized pulp tissue in an ectopic root transplantation model after a short 21-day transplantation period [145]. More recently, Disanayaka et al. demonstrated the successful regeneration of vascularized dental pulp tissue after transplantation of DPSCs or DPSCs and HUVECs encapsulated in a commercially available hydrogel. Root fragments containing cocultures displayed a more pronounced vascularization, ECM deposition, and tissue mineralization in comparison to DPSCs alone, indicating the importance of coordinated cell-cell interactions [58]. Preconditioning DPSCs by means of hypoxia, prior to transplantation, evoked a higher number of blood vessels in the regenerated tissue compared to the control conditions [146]. Although the ectopic root transplantation model has been widely applied, both the shape of the root canals and the implemented size of the apical foramen have been prone to variability [58, 143–146], which leads to the question whether smaller apical openings would interfere with normal tissue regeneration in the “coronal” part of the emptied root canal [143]. Another important aspect which definitely needs to be taken into account during differentiation and tissue engineering is the specific microenvironment at the time of regeneration. This would require the in situ transplantation of DPSCs in (partially) pulpectomized teeth in (larger) animal models. In 2004, Iohara et al. reported the formation of reparative dentin after treatment of an amputated canine pulp with an autologous DPSC pellet incubated with bone morphogenetic protein-2 [147, 148]. Over the past decade this research group and others have successfully performed in situ transplantsations (of different subpopulations) of DPSCs to completely regenerate vascularized pulp tissue [149–156]. In 2013, the first solid steps towards the clinical application of DPSCs were taken. After careful karyotyping and excluding potential tumor formation by the stem cells, Iohara et al. reported the regeneration of a vascularized and innervated dentin/pulp complex following transplantation of a clinical-grade subpopulation of DPSCs in pulpectomized canine teeth with an apical opening of 0.6 mm [152, 157].

With regard to the regenerative potential of SCAPs, Sonoyama et al. demonstrated their ability to form a dentin/pulp complex when transplanted with HA/TCP particles in immunocompromised mice. The human origin of the dentin-producing cells suggested the differentiation of SCAPs into odontoblast-like cells [158]. Similar results were also found by Huang et al., indicating the de novo regeneration of vascularized pulp-like tissue after the ectopic transplantation of an emptied human root canal containing a PLGA scaffold seeded with SCAPs [143]. Moreover, analysis showed a more continuous and thicker layer of dentin matrix in comparison to similar constructs containing DPSCs [143]. Subcutaneous implantation of SCAP-based cell sheet-derived pellets in immunodeficient mice also led to the development of a vascularized dentin/pulp complex with a continuous layer of dentin matrix [159].

As previously mentioned, FSCs originate from the dental follicle, a loose connective tissue surrounding developing teeth [11]. As the dental follicle during tooth development gives rise to the periodontium, research has mainly focused on the ability of FSCs to regenerate cementum and periodontal ligament [160–167]. Regarding their ability to form dental pulp tissue, Guo et al. indicated the establishment of an odontoblast-like cell layer as well as the formation of (pre)dentin in the omental pouch of adult rats after transplantation of rat FSCs and treated dentin matrix (TDM) [168]. In an attempt to engineer a complete tooth root, transplantation of similar constructs containing rat or human FSCs led to the regeneration of a dentin/pulp complex as well as cementum and periodontal ligament (PDL) [169, 170]. In line with these findings, Jiao et al. described the formation of vascularized dental pulp-like tissue after subcutaneous transplantation of human FSCs encapsulated within cryopreserved TDM [171]. When comparing the regenerative potential of FSCs and SCAPs, no significant differences were found despite their differential expression of protein markers in vitro. Both stem cell populations were able to regenerate a vascularized dentin/pulp-like complex following 8 weeks of transplantation in nude mice [51]. To date, no reports are available regarding the use of PDLSCs in dental pulp regeneration. Given their developmental origin, these stem cells have been mainly investigated for their potential application in periodontal regeneration.

6. Clinical Application of DSCs and Its Challenges

Despite the promising outcomes of DSC transplantation in a preclinical setting, the progression of DSCs from bench to bedside still holds some major challenges. Standardized cell isolation procedures, for example, are indispensable to safeguard the clinical safety, reproducibility, and efficacy of DSC therapy [172]. However, the extraction of third molars as well as the isolation of DSCs is currently being performed using diverse isolation procedures on donors of different ages with molars at different stages of development, which not only impairs in-depth comparison of experimental outcomes but also hinders the development of a standardized treatment protocol [15, 23, 173, 174]. Next to consistent isolation procedures, the clinical implementation of DSCs also entails the upscale production of these stem cells in xeno-free culture conditions, in order to provide an adequate amount of cells without any contamination of potential infectious agents [175–177]. Nevertheless, due to the inherent batch-to-batch variety as well as the current lack of reliable study protocols regarding the use of human blood-derived products as a potential alternative, more research is required before any educated decision can be taken by both scientists and regulatory agencies [178–180]. In addition to the challenges associated with the processing and culturing of DSCs, one also needs to take into account the intrinsic behavior of the stem cells, as it can be influenced by a broad range of
different donor-related factors, such as (oral) health, age, and orthodontic tooth movement [23].

Although numerous studies have elaborately described the immunomodulatory effects of DSCs in vitro, little is known concerning the effects of allogeneic DSC transplantation in vivo [19, 181–189]. Tomic et al., for example, reported the formation of granulomatous tissue after xenogeneic transplantation of human DPSCs and FSCs in immunocompetent mice [190]. When transplanting rat DPSCs in mice suffering from colitis, on the other hand, a clear reduction of inflammation was observed [191]. There were also no signs of immune rejection after injection of human SHEDs in a canine model of muscular dystrophy [192]. In line with these findings, conditioned medium of SHEDs was found to alleviate autoimmune encephalomyelitis as well as to improve the cognitive function in a mouse model of Alzheimer’s Disease through the induction of anti-inflammatory M2-phenotype microglia [93, 193]. Nevertheless, the outcome of allogeneic DSC transplantation for dental tissue engineering purposes in particular remains largely unknown, as most ectopic transplantation models are performed in immunocompromised mice and most in situ models apply autologous DSCs [58, 143–158, 162, 170, 194–197]. More research is thus required with respect to the immunomodulatory behavior of allogeneic DSCs in vivo and potential graft-versus-host responses.

When making the switch from bench to bedside it is also important to include sufficient patient-centered outcomes. All too often, dental clinical trials focus on technical, clinician-centered outcomes instead of patient-centered outcomes. Developing a standardized set of core outcomes could help overcome this fixation with clinician-based outcomes and lead to more consistent study designs [198].

Despite these challenges, a few clinical studies using DSC-based therapies are currently recruiting participants (Table 3). In India, a clinical study is currently ongoing in which patients suffering from chronic periodontitis receive a local injection of allogeneic human DPSCs in order to improve periodontal tissue regeneration (ClinicalTrials.gov NCT02523651). Allogeneic DPSCs are also being applied in a clinical trial in China, investigating the effect of DPSCs on osseointegration of dental implants (NCT02731586). Also in China, a second clinical trial focuses on the revitalization of young immature permanent teeth with necrotic pulps using autologous SHEDs (NCT01814436). Finally, Nagpal et al. announced a study protocol for evaluating safety and feasibility of autologous DPSC-based stem cell therapy in patients with chronic disability after stroke; however, this study is not yet recruiting participants [91].

7. Conclusion and Future Perspectives

Taken together, DSCs are considered suitable candidates for cell-based treatment strategies and tissue engineering applications. There is abundant evidence supporting the angiogenic, neuroprotective, and neurotrophic actions of the DSC secretome (Figure 1). These inherent properties can even be augmented by pretreating DSCs prior to their transplantation. In particular hypoxia and hypoxia mimicking agents show great potential to improve stem cell survival and boost the DSC secretome. Up until now, most of the pretreatment studies have been focusing on improving the angiogenic
effects of DSCs; therefore more research into the possible enhancement of their neurotropic/neuroprotective properties is warranted. In addition to their paracrine effects, DSCs have also been described to have the ability to differentiate into endothelial cells as well as neural cell types (Figure 1). Unfortunately, a wide variety of differentiation protocols have been used, resulting in highly variable outcomes and making it difficult to compare study outcomes but even more so to compare different DSC populations. Furthermore, often different parameters are used to assess successful differentiation.

Based on their origin, DSCs are expected to be ideal candidates for the regeneration of dental tissues such as the dental pulp and the periodontal ligament. Successful dental pulp regeneration has already been reported for DPSCs, SCAPs, and FSCs, whereas PDLSCs hold great potential for the regeneration of periodontal tissues. Furthermore, DPSCs, SHEDs, and PDLSCs have already been reported to improve regeneration after peripheral nerve injury by promoting remyelination, blood vessel formation, and nerve regeneration. These encouraging results contributed to the approval of two clinical studies that are currently recruiting participants and are thereby taking the first steps to introducing DSC-based therapies into the clinic.

### Competing Interests
The authors declare that they have no competing interests.

### Authors’ Contributions
Jessica Ratajczak and Annelies Bronckaers equally contributed to this paper.

### References


Y. Sugimura-Wakayama, W. Katagiri, M. Osugi et al., “Peripheral nerve regeneration by secretomes of stem cells from human


Submit your manuscripts at
http://www.hindawi.com